Nocion Therapeutics, a Watertown, MA-based clinical-stage biopharmaceutical company, raised $62M in Series B funding.
The round, which brought the total amount to $122M, was led by Arkin Bio Capital and Monograph Capital with participation from new and existing investors Canaan Partners, F-Prime Capital, Mass General Brigham Ventures, Mission BioCapital and Osage University Partners. In conjunction with the Series B financing, Pini Orbach, Ph.D., of Arkin Bio Capital and Freddie Dear of Monograph Capital will join Nocion’s Board of Directors.
The company intends to use the funds to evaluate the lead program, taplucanium dry powder for inhalation, in a Phase 2b study in chronic cough patients.
Led by CEO Dr. Richard Batycky, Nocion Therapeutics is a biopharmaceutical company developing novel small molecule CSCBs, “nocions,” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain. It works to safely alleviate suffering for patients with conditions arising from activated sensory neurons. Working with Harvard’s Office of Technology Development, Nocion was founded on an exclusive license to foundational intellectual property from Harvard University and Boston Children’s Hospital.
